Cognivue, Inc. Information

Cognivue is a risk assessment test that identifies changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It is the world's first FDA-Cleared computerized test of cognitive function. Cognivue was designed to objectively, quantitatively and reliably identify changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It allows clinicians the opportunity to establish a baseline cognitive score that can be monitored over time. Cognivue measures and monitors cognitive health by testing 4 key cognitive domains. This 10 minute test measures tracking movement, vision, perception and memory of letters, words, shapes and motion. Unlike paper and pencil cognitive testing, Cognivue is based on neurophysiology and psychophysical research. Upon completion of the test, Cognivue immediately creates a report with a clinical risk score of cognitive health. Using the patient's risk score, you will be able to determine the patient's risk stratification and proper course of action to improve patient care.